InvoX Pharma has acquired F-star Therapeutics for $161 million

InvoX Pharma Limited has acquired F-star Therapeutics for $161 million.

Babraham Research Campus, a leader in bispecific antibodies for immunotherapy, is participating in phase II cancer trials in Europe and the United States, for which the deal will provide funding for follow-up.

How do F-star bispecific antibodies compare to standard antibodies?  (62961514)
How do F-star bispecific antibodies compare to standard antibodies? (62961514)

The deal — which equates to $7.12 per share — has been approved by the UK’s regulatory agency responsible for enforcement of national security law and investment and the Committee on Foreign Investment in the United States. F-star also has a US base in Cambridge, Massachusetts.

“The closing of the transaction significantly strengthens InvoX’s pharmaceutical business, accelerating the construction of a pipeline with a primary focus on oncology and respiratory therapies,” said Ben Twogood, CEO of InvoX. “More importantly, it provides capital to ensure that enrolled patients continue to have access.” In F-star clinical studies on access to life-saving therapies.

“We are pleased to have reached agreement with US regulators after a substantive and thorough discussion. This authorization is a clear signal that governments understand the importance of collaboration between trusted parties to advance patient-centered innovations in biotechnology.

We believe this will lay a solid foundation and understanding for our future steps and leave us well positioned to continue growing around the world with more investment opportunities. We are also excited to welcome these F-star employees and look forward to working with them as we invest in the company to advance and grow the medical pipeline to realize the full potential of the platform.”

Phase II F-star trials include patients with PD-1-refractory acquired head and neck cancer, and checkpoint suppression-naïve patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL). It also has more previous clinical studies underway here and in the United States.

UK-based inVox Pharma, established in March 2021, is a wholly owned subsidiary of Sino Biopharm, one of the top 40 global pharmaceutical companies with over 24,000 employees and headquartered in Hong Kong.

InvoX is a fully integrated biopharmaceutical company focused on research and development activities and business development outside of China. Her primary focus is Oncology and Respiratory Therapies.

DISCLAIMER:- Denial of responsibility! is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email at The content will be deleted within 24 hours.

Read original article here

Leave a Comment